Sign In
Last checked at 
1 Dec 2014 15:15
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Retirement of Director and
appointment of new Company Secretary
1 December 2014: As foreshadowed in the Company's announcement on 30 September 2014 Mr. James Malthouse has today retired as a director of the Company and as Company Secretary.
Mr. Geoffrey Ellis, the Finance Director, has today been appointed as Company Secretary.
- Ends-
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | |
Dr. Ian Pike, Chief Operating Officer | Tel: +44 (0)1932 865065 |
Geoff Ellis, Finance Director | |
Nominated Adviser | |
Cenkos | |
Mark Connelly/Callum Davidson finnCap Geoff Nash | Tel: +44 (0)20 7397 8900 Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.
Follow the stocks
